EXACT Sciences reported a GAAP loss of $180.937 million for the first three months of 2022, up 5.8 times from $31.164 million in the previous year. Revenue increased 21% to $486.571 million from $402.077 million a year earlier.

EXACT Sciences' GAAP loss for 2021 was $595.625 million, down 27.7% from $823.605 million in the previous year. Revenue increased 18.5% to $1.767 billion from $1.491 billion a year earlier.

Exact Sciences has acquired PreventionGenetics, which owns a clinical laboratory for detecting hereditary cancer and tight genetic diseases. Exact Sciences paid $190 million, half of which was paid in Exact common stock.

EXACT Sciences reported a GAAP loss of $375.014 million for 9M 2021, down 7.5% from $405.273 million in the previous year. Revenues increased 26.1% to $1.293 billion from $1.025 billion a year earlier.